[SCHEDULE 13G/A] Bolt Biotherapeutics, Inc. SEC Filing
Bolt Biotherapeutics (BOLT) disclosure shows Tang Capital affiliates and Kevin Tang collectively report beneficial ownership of 166,879 shares of common stock, representing 8.7% of the class on a post-reverse-split basis. The holders report shared voting and dispositive power over these shares and no sole voting or dispositive power. The percentage is calculated using the issuer's disclosed outstanding share count adjusted for a one-for-twenty reverse stock split. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Bolt Biotherapeutics (BOLT) ha dichiarato che gli affiliati di Tang Capital e Kevin Tang detengono congiuntamente la titolarit脿 beneficiaria di 166.879 azioni ordinarie, pari al 8,7% della categoria su base post-split inverso. I soggetti riportano di avere potere di voto e di disposizione condiviso su queste azioni e di non avere potere di voto o di disposizione esclusivo. La percentuale 猫 stata calcolata usando il numero di azioni in circolazione comunicato dall'emittente, rettificato per uno split azionario inverso di una azione ogni venti. La comunicazione include una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente.
Bolt Biotherapeutics (BOLT) revela que los afiliados de Tang Capital y Kevin Tang poseen conjuntamente la propiedad beneficiaria de 166.879 acciones ordinarias, que representan el 8,7% de la clase en base posterior a la consolidaci贸n inversa. Los titulares informan que tienen poder de voto y de disposici贸n compartido sobre estas acciones y que no tienen poder de voto ni de disposici贸n exclusivo. El porcentaje se calcula usando el n煤mero de acciones en circulaci贸n divulgado por el emisor, ajustado por una consolidaci贸n inversa de una por veinte. La presentaci贸n incluye una certificaci贸n de que los valores no se adquirieron para cambiar o influir en el control del emisor.
Bolt Biotherapeutics (BOLT) 瓿奠嫓鞐� 霐半ゴ氅� Tang Capital 瓿勳棿靷摛瓿� Kevin Tang電� 頃╉晿鞐� 166,879欤� 氤错喌欤检潣 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 鞐暋氅措秳頃�(1欤� 雽� 20欤�) 氚橃榿 頉� 旮办鞙茧 頃措嫻 膦呺鞚� 8.7%鞐� 頃措嫻頃╇媹雼�. 氤挫湢鞛愲摛鞚� 鞚� 欤检嫕霌れ棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頄堨溂氅� 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 鞐嗠嫟瓿� 氚濏様鞀惦媹雼�. 牍勳湪鞚� 氚滍枆靷皜 瓿奠嫓頃� 鞙犿喌欤检嫕靾橃棎 鞐暋氅措秳頃犾潉 鞝侅毄頃� 靷办稖頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 氚滍枆靷潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃橂姅 鞚胳靹滉皜 韽暔霅橃柎 鞛堨姷雼堧嫟.
Bolt Biotherapeutics (BOLT) d茅clare que des affili茅s de Tang Capital et Kevin Tang d茅tiennent conjointement la propri茅t茅 b茅n茅ficiaire de 166 879 actions ordinaires, repr茅sentant 8,7% de la cat茅gorie sur une base post-fractionnement invers茅. Les d茅tenteurs indiquent exercer un pouvoir de vote et un pouvoir de disposition partag茅s sur ces actions et ne d茅tenir aucun pouvoir de vote ou de disposition exclusif. Le pourcentage est calcul茅 脿 partir du nombre d'actions en circulation communiqu茅 par l'茅metteur, ajust茅 pour un regroupement d'actions de une pour vingt. Le d茅p么t inclut une attestation pr茅cisant que les titres n'ont pas 茅t茅 acquis dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Bolt Biotherapeutics (BOLT) Offenlegung zeigt, dass Tang Capital-Affiliates und Kevin Tang gemeinsam wirtschaftliches Eigentum an 166.879 Stammaktien melden, was 8,7% der Klasse auf Grundlage nach dem Reverse-Split entspricht. Die Inhaber geben an, 眉ber diese Aktien geteilte Stimm- und Verf眉gungsrechte zu besitzen und keine alleinigen Stimm- oder Verf眉gungsrechte. Der Prozentsatz wurde unter Verwendung der vom Emittenten angegebenen ausstehenden Aktienzahl berechnet, angepasst f眉r einen Reverse-Split eins zu zwanzig. Die Meldung enth盲lt eine Bescheinigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
- Material disclosed stake: Ownership of 166,879 shares equals 8.7% of class, a clearly reportable, material position.
- Transparency: Reporting identifies all related filing entities and clarifies shared voting and dispositive arrangements.
- No sole control: Reported holders have 0 shares of sole voting or dispositive power, limiting clear governance control.
- No indication of strategic intent: Certification states shares were not acquired to change or influence control, so no stated proactive engagement.
Insights
TL;DR: Tang Capital group holds a material, passive stake (~8.7%) in BOLT with shared control, indicating a reported significant investor position without control intent.
The filing discloses a >5% position which is material for ownership metrics and liquidity considerations. Ownership is reported as shared voting/dispositive power across related entities and an individual, which can complicate precise attribution but confirms consolidated economic exposure. The certification of non-control purpose limits immediate governance implications. This disclosure could prompt market attention given the stake size relative to the float adjusted by a reverse split.
TL;DR: Ownership is significant but explicitly characterized as not aimed at changing control; governance influence appears limited by shared, not sole, powers.
The report shows shared authority among affiliated entities and the named individual, without any sole voting or dispositive rights. From a governance perspective, shared power holders may still coordinate, but the explicit certification that the shares were not acquired to influence control reduces immediate regulatory or proxy implications. Monitor for future amendments or Schedule 13D if intentions change.
Bolt Biotherapeutics (BOLT) ha dichiarato che gli affiliati di Tang Capital e Kevin Tang detengono congiuntamente la titolarit脿 beneficiaria di 166.879 azioni ordinarie, pari al 8,7% della categoria su base post-split inverso. I soggetti riportano di avere potere di voto e di disposizione condiviso su queste azioni e di non avere potere di voto o di disposizione esclusivo. La percentuale 猫 stata calcolata usando il numero di azioni in circolazione comunicato dall'emittente, rettificato per uno split azionario inverso di una azione ogni venti. La comunicazione include una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente.
Bolt Biotherapeutics (BOLT) revela que los afiliados de Tang Capital y Kevin Tang poseen conjuntamente la propiedad beneficiaria de 166.879 acciones ordinarias, que representan el 8,7% de la clase en base posterior a la consolidaci贸n inversa. Los titulares informan que tienen poder de voto y de disposici贸n compartido sobre estas acciones y que no tienen poder de voto ni de disposici贸n exclusivo. El porcentaje se calcula usando el n煤mero de acciones en circulaci贸n divulgado por el emisor, ajustado por una consolidaci贸n inversa de una por veinte. La presentaci贸n incluye una certificaci贸n de que los valores no se adquirieron para cambiar o influir en el control del emisor.
Bolt Biotherapeutics (BOLT) 瓿奠嫓鞐� 霐半ゴ氅� Tang Capital 瓿勳棿靷摛瓿� Kevin Tang電� 頃╉晿鞐� 166,879欤� 氤错喌欤检潣 鞁れ鞝� 靻岇湢甓岇潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 鞐暋氅措秳頃�(1欤� 雽� 20欤�) 氚橃榿 頉� 旮办鞙茧 頃措嫻 膦呺鞚� 8.7%鞐� 頃措嫻頃╇媹雼�. 氤挫湢鞛愲摛鞚� 鞚� 欤检嫕霌れ棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頄堨溂氅� 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 鞐嗠嫟瓿� 氚濏様鞀惦媹雼�. 牍勳湪鞚� 氚滍枆靷皜 瓿奠嫓頃� 鞙犿喌欤检嫕靾橃棎 鞐暋氅措秳頃犾潉 鞝侅毄頃� 靷办稖頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 氚滍枆靷潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃橂姅 鞚胳靹滉皜 韽暔霅橃柎 鞛堨姷雼堧嫟.
Bolt Biotherapeutics (BOLT) d茅clare que des affili茅s de Tang Capital et Kevin Tang d茅tiennent conjointement la propri茅t茅 b茅n茅ficiaire de 166 879 actions ordinaires, repr茅sentant 8,7% de la cat茅gorie sur une base post-fractionnement invers茅. Les d茅tenteurs indiquent exercer un pouvoir de vote et un pouvoir de disposition partag茅s sur ces actions et ne d茅tenir aucun pouvoir de vote ou de disposition exclusif. Le pourcentage est calcul茅 脿 partir du nombre d'actions en circulation communiqu茅 par l'茅metteur, ajust茅 pour un regroupement d'actions de une pour vingt. Le d茅p么t inclut une attestation pr茅cisant que les titres n'ont pas 茅t茅 acquis dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Bolt Biotherapeutics (BOLT) Offenlegung zeigt, dass Tang Capital-Affiliates und Kevin Tang gemeinsam wirtschaftliches Eigentum an 166.879 Stammaktien melden, was 8,7% der Klasse auf Grundlage nach dem Reverse-Split entspricht. Die Inhaber geben an, 眉ber diese Aktien geteilte Stimm- und Verf眉gungsrechte zu besitzen und keine alleinigen Stimm- oder Verf眉gungsrechte. Der Prozentsatz wurde unter Verwendung der vom Emittenten angegebenen ausstehenden Aktienzahl berechnet, angepasst f眉r einen Reverse-Split eins zu zwanzig. Die Meldung enth盲lt eine Bescheinigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many BOLT shares does Tang Capital report owning?
What percentage of BOLT does the reported stake represent?
Do the reporting persons have voting control over the shares?
Did the filers state an intent to change or influence control of BOLT?
Which entities and individuals filed the Schedule 13G/A?
